Patients with moderate to severe AD can benefit from biologics targeting cytokines such as IL-4/13, IL-13, IL-31, yet many patients do not achieve complete or near-complete remission of their condition [8–10]. This evidence concerns the gene IL4 and Alzheimer disease.